Interferon-Inducible Protein 10, but Not Monokine Induced by Gamma Interferon, Promotes Protective Type 1 Immunity in Murine *Klebsiella pneumoniae* Pneumonia

Xianying Zeng, Thomas A. Moore, Michael W. Newstead, Jane C. Deng, Steven L. Kunkel, Andrew D. Luster, and Theodore J. Standiford

*Departments of Pathology and Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, and Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts*

Received 7 June 2005/Returned for modification 21 July 2005/Accepted 26 August 2005

CXC chemokines that lack the ELR motif, including interferon-inducible protein 10 [IP-10 (CXCL10)] and monokine induced by gamma interferon (IFN-γ) [MIG (CXCL9)], have been shown to mediate the generation of type 1 immune responses. In this study, we found that intrapulmonary administration of the gram-negative bacterium *Klebsiella pneumoniae* resulted in the local and systemic expression of IP-10, followed sequentially by MIG expression. MIG mRNA expression in the lungs of *Klebsiella*-infected mice required the endogenous production of IFN-γ, whereas IP-10 was expressed in both an IFN-γ-dependent and an IFN-γ-independent fashion. Antibody-mediated neutralization of IP-10 resulted in reduced bacterial clearance and decreased survival, whereas bacterial clearance was unaltered in mice treated with anti-MIG antibody. Impaired bacterial clearance in anti-IP-10 antibody-treated mice was associated with significant reductions in the number and/or activational status of NK and NK-T cells, CD4+ T cells, and γδ T cells, as well as a reduction in the expression of IFN-γ. Conversely, the transient transgenic expression of murine IP-10 using adenovirus-mediated gene transfer resulted in improved bacterial clearance when IP-10 adenovirus was given concomitant with intrapulmonary bacterial challenge. These results indicate that IP-10 is an important component of innate immunity against extracellular bacterial pathogens of the lung and may represent a candidate molecule for immunotherapy in the setting of severe respiratory tract infection.

Innate, or natural, immunity is the principal pathway for effective elimination of most bacterial pathogens of the lung (25). The two main phagocytic cells that constitute innate immunity in the lung are resident alveolar macrophages and recruited neutrophils (6, 20, 35, 36). Innate immune responses are enhanced in the presence of type 1 cytokines, including interleukin-12 and gamma interferon (IFN-γ) (14, 24, 30). Type 1 cytokine responses are absolutely required for the effective killing of intracellular pathogens and have also been shown to contribute to effective immunity against extracellular gram-positive and gram-negative bacteria (5, 8, 13, 24, 30, 32). In particular, innate responses against *Streptococcus pneumoniae* and *Klebsiella pneumoniae* are impaired in animals deficient in IFN-γ, whereas the exogenous administration or overexpression of IFN-γ can augment the clearance of bacteria from the lungs of immunocompetent mice (8, 19, 24, 30, 32). In most intracellular infections, IFN-γ is elaborated by T and NK cells in an antigen-specific fashion in response to dendritic cell-derived signals (4). IFN-γ can also be expressed early in bacterial infection in a non-antigen-specific fashion by lung macrophages, NK cells, and γδ T cells, either directly in response to microbial signals or in response to host-derived cytokines (8, 9, 23).

Chemokines are a large family of proteins that mediate the movement and activation of diverse groups of inflammatory cells (22). A subfamily of chemokines that plays a key role in promoting type 1 immune responses is the ELR− CXC chemokines. Specifically, the ELR− CXC chemokines, including interferon-inducible protein 10 [IP-10 (CXCL10)], monokine induced by gamma interferon [MIG (CXCL9)], and interferon-inducible T-cell chemoattractant (CXCL11), exert chemotactic effects on various mononuclear cell populations involved in type 1 immunity (11). In vitro, ELR− CXC chemokines stimulate the migration of monocytes, NK cells, Th1 T cells, and NK-T cells (16, 33). Additionally, these chemokines can activate NK cells and induce the production of IFN-γ from effector T cells (12, 33). In vivo, we and others have found that the intrapulmonary transient transgenic expression of mouse or human IP-10 in mice using adenoviral gene transfer resulted in the early accumulation and activation of NK and NK-T cells within the lung, followed by the delayed accumulation of CD4+ T cells (27, 40). The G protein-coupled receptor CXCR3 serves as the sole receptor for ELR− CXC chemokines. CXCR3 is expressed on activated T cells, predominantly of the Th1 phenotype, as well as on NK cells, NK-T cells, and a subset of circulating memory CD4+ and CD8+ T cells (21).

ELR− CXC chemokines have been closely linked with the generation of Th1-type inflammatory responses in vivo. For example, IP-10 and/or MIG is expressed in a wide variety of...
inflammatory disease states manifested by overzealous type 1 inflammation, including atherosclerosis, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, and allograft rejection (1, 3, 28, 41). Moreover, both IP-10 and MIG have been shown to participate in the generation of the idiopathic pneumonia syndrome complicating experimental allogeneic bone marrow transplantation, with these molecules functioning in an additive fashion to promote lung injury in this model (15). Conversely, IP-10 has been shown to inhibit the development of allergic airway inflammation (39). These chemokines are also expressed in increased amounts in infections that require vigorous type 1 immunity, including antimicrobial responses against mouse hepatitis virus and intracellular microbial pathogens such as Toxoplasma gondii, Mycobacterium bovis, and Rickettsia conorii (2, 17, 18, 37). Importantly, mice deficient in IP-10 display impaired clearance of mouse hepatitis virus from the brain, which is associated with reduced CD4+ and CD8+ T-cell influx and IFN-γ production (10). Recently, IP-10, MIG, and interferon-inducible T-cell chemokine have been shown to be expressed in a murine model of intrapulmonary challenge with the gram-negative coccobacillus Bordetella bronchiseptica and reduced influx of T cells and NK cells and modestly impaired pulmonary clearance of B. bronchiseptica were observed in Cxcr3−/− mice relative to wild-type-infected controls (38). Interestingly, in addition to effects on recruitment and activation of various myeloid cell populations, members of the ELR+ CXC chemoattractant have been shown to be expressed in a murine model of type 1 immunity in lung antibacterial host defense. The beneficial effects of IP-10 on innate immunity in Klebsiella pneumoniae and that IP-10 but not MIG is an important component of type 1 immunity in lung antibacterial host defense. The beneficial and that IP-10 but not MIG is an important component of type 1 immunity, including antimicrobial responses against mouse hepatitis virus and intracellular microbial pathogens such as Toxoplasma gondii, Mycobacterium bovis, and Rickettsia conorii (2, 17, 18, 37). Importantly, mice deficient in IP-10 display impaired clearance of mouse hepatitis virus from the brain, which is associated with reduced CD4+ and CD8+ T-cell influx and IFN-γ production (10). Recently, IP-10, MIG, and interferon-inducible T-cell chemokine have been shown to be expressed in a murine model of intrapulmonary challenge with the gram-negative coccobacillus Bordetella bronchiseptica and reduced influx of T cells and NK cells and modestly impaired pulmonary clearance of B. bronchiseptica were observed in Cxcr3−/− mice relative to wild-type-infected controls (38). Interestingly, in addition to effects on recruitment and activation of various myeloid cell populations, members of the ELR+ CXC chemoattractant have been shown to be expressed in a murine model of type 1 immunity in lung antibacterial host defense. The beneficial effects of IP-10 on innate immunity in Klebsiella pneumoniae and that IP-10 but not MIG is an important component of type 1 immunity in lung antibacterial host defense. The beneficial.
Isolation and reverse transcription-PCR amplification of whole-lung mRNA.

Whole lung was harvested, immediately snap-frozen in liquid nitrogen, and stored at -70°C; then reverse transcription (RT)-PCR was performed as previously described (40). Briefly, total cellular RNA from the frozen lungs were isolated, reversed transcribed into cDNA, and then amplified using specific primers for mIP-10 and mMIG with β-actin serving as a control. The primers had the sequences 5'-ATC ATC CCT GCG AGC CTA TC-3' and 5'-GAA CTG ACG AGC CTG AGC TA-3' for IP-10; 5'-ACATTCTCGGACTTCACTCC A-3' and 5'-CTAGGCAGGTTTGATCTCCGT-3' for murine MIG; and 5'-ATG GAT GAC GAC ATC GCT C-3' and 5'-GAT TCC ATA CCC AGG AGG TTT GAG C-3' for β-actin.

FIG. 1. Expression of IP-10 and MIG mRNA in lung, liver, and spleen after i.t. administration of K. pneumoniae. Animals were administered 5 × 10^7 CFU K. pneumoniae i.t., and then organs were harvested at various times after bacterial administration. mRNA levels in lung, liver, and spleen homogenates are shown in panels A, B, and C, respectively. The top of each panel shows results of RT-PCR, whereas the bottom of each panel shows results of real-time PCR. For RT-PCR, 30 cycles were performed for IP-10 or MIG, while 25 cycles were performed for β-actin. For real-time PCR, fold increases represent that over untreated lung. n was three organs per each time point that was combined (RT-PCR) or averaged (real-time PCR). kp, Klebsiella-infected mice.

A. IP-10 MIG β-actin Lung

B. IP-10 MIG β-actin Liver

C. IP-10 MIG β-actin Spleen

<table>
<thead>
<tr>
<th>Hours Post-Infection (kp)</th>
<th>Fold Increase mIP-10 and mMIG mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninfected</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td></td>
</tr>
<tr>
<td>72</td>
<td></td>
</tr>
</tbody>
</table>

kp, Klebsiella-infected mice.
AGG G-3 for β-actin. After amplification, the samples (20 μl) were separated on a 2% agarose gel containing ethidium bromide at 5 μg/100 ml (Sigma; 10 mg/ml), and bands were visualized and photographed using UV transillumination.

**Real-time quantitative RT-PCR.** Measurement of gene expression was performed utilizing the ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA) as previously described (40). Briefly, primers and probes for β-actin, IP-10, MIG, and IFN-γ were designed using Shortcut to Primer Express software (Applied Biosystems). The primers, placed in different exons, were tested not to amplify genomic DNA. Primer and probe nucleotide sequences for mIP-10 were as follows: forward primer 5’-CTG AGG ACC ATA-3’ and reverse primer 5’-CTC AAC AGG GGA GGA T-3’; forward primer 5’-TGA AGT CCG CGG TCT TTT TTC-3’ and reverse primer 5’-GGG TTC TCT CTC GAA CTC CAC ACT-3’; TaqMan probe 5’(6-carboxy-tetramethylrhodamine [TAMRA])-FAM GGG CAT CCT CCT GGA (6-carboxytetramethylrhodamine [TAMRA])-3’/mMIG; forward primer 5’-CTG CCG CCT AGT TCT GAG A-3’ and reverse primer 5’-CAG CCA GAA ACA GCC AGT AG-3’; TaqMan probe 5’ (FAM)-CAC ACT GCA TCT TGG CTG AGC TC (TAMRA)-3’; and TaqMan probe 5’ (FAM)-CTT GAA ATC ATC CCT CGG ACC C (TAMRA)-3’ for mIFN-γ. Primer and probe nucleotide sequences for mIP-10 were as follows: forward primer 5’-CCG TGA AAA GAT GAC CCA GAT C-3’; reverse primer 5’-CAG ATC GGT GGT AAC GT-3’, and TaqMan probe 5’(FAM)-TTT GAG ACC TTC AAC ACC CCA GGC A (TAMRA)-3’. Specific thermal cycling parameters used with the TaqMan one-step RT-PCR master mix reagent kit included 30 min at 48°C, 10 min at 95°C, and annealing/extension at 60°C for 1 min. Relative quantitation of IP-10 or MIG mRNA levels was plotted as change (n-fold) relative to untreated control. All experiments were performed in duplicate.

**Murine cytokine ELISA.** Murine IP-10 and MIG were quantitated using a modification of a double-ligand method as previously described (40). Standards were one-half-log dilutions of murine recombinant cytokines from 1 pg/ml to 100 ng/ml. This ELISA method consistently detected murine IP-10 or MIG concentrations above 50 pg/ml. The ELISAs did not cross-react with other cytokines tested.

**Statistical analysis.** Survival curves were compared using the log-rank test. For other data, statistical significance was determined using the unpaired t test. All calculations were performed using the Prism 3.0 software program for Windows (GraphPad Software, San Diego, CA). All mean data shown are expressed as means plus or minus standard errors of the means.

**RESULTS**

**Induction of IP-10 and MIG mRNA after i.t. administration of K. pneumoniae.** To determine the effect of i.t. *K. pneumoniae* administration on the expression of IP-10 and MIG mRNA levels, C57B/6j mice were administered *K. pneumoniae* (5 × 10^9^ CFU). Lungs, liver, and spleen were harvested at 12, 24, 48, and 72 h after i.t. administration. *K. pneumoniae* administration and chemokine mRNA levels were determined by RT-PCR (Fig. 1A, top panel) and real-time quantitative PCR (bottom panel). As shown in Fig. 1A, there was a time-dependent increase in the expression of IP-10 and MIG mRNA in the lung, with maximal expression occurring at 48 h for IP-10 (>100-fold increase over the uninfected control) and 72 h for MIG (70-fold increase over the uninfected control). In addition, we observed substantial, albeit somewhat smaller, increases in the expression of IP-10 and MIG mRNA in liver (Fig. 1B) and spleen (Fig. 1C), with temporal patterns of expression similar to those observed in the lung.

**Induction of IP-10 and MIG protein after i.t. administration of K. pneumoniae.** We next assessed the production of IP-10 and MIG protein in whole lung after i.t. *K. pneumoniae* administration. As shown in Fig. 2, i.t. *K. pneumoniae* challenge resulted in an increase in IP-10 protein expression by 24 h, a maximal sevenfold increase in IP-10 levels at 48 h, and continued production out to 96 h. *K. pneumoniae* expression resulted in a somewhat delayed expression of MIG, with a maximal fivefold increase in MIG protein levels at 48 h, compared to that observed in the untreated control lung. MIG levels remained elevated at 96 h after i.t. *K. pneumoniae* administration.

**Contribution of IFN-γ to the induction of IP-10 and MIG in murine Klebsiella pneumoniae.** To determine if the expression of MIG and/or IP-10 mRNA and protein was dependent on the endogenous production of IFN-γ in Klebsiella pneumoniae, we assessed the expression of MIG and IP-10 mRNA by quantitative real-time PCR (Fig. 3A) and protein analysis (Fig. 3B) in whole lungs of wild-type and IFN-γ-deficient mice after i.t. *K. pneumoniae* administration. As shown in Fig. 3, intrapulmonary bacterial administration resulted in substantial upregulation of MIG mRNA in wild-type animals at 48 h, whereas no induction of MIG message was detected in IFN-γ-deficient animals. In contrast, a modest but significant induction (14.3-fold induction) of IP-10 mRNA was observed in IFN-γ-knockout animals infected with Klebsiella relative to uninfected animals. However, the expression of IP-10 was substantially reduced from that observed in wild-type mice challenged with *K. pneumoniae*. Consistent with the mRNA data, we observed a small but appreciable induction of IP-10 protein in the lungs of IFN-γ-knockout animals 72 h after i.t. challenge with Klebsiella (Fig. 3B) (P, <0.05), whereas no increase in MIG was noted in IFN-γ-knockout mice at either 48 or 72 h after *K. pneumoniae* administration. These observations indicate that the expression of both MIG and IP-10 in the lungs of Klebsiella-infected animals is largely dependent upon IFN-γ, although other signals can serve to induce IP-10, but not MIG, in pneumonia independently of IFN-γ.

**Effect of anti-murine IP-10 or anti-murine MIG antibody administration on bacterial clearance in murine Klebsiella pneumoniae.** Experiments were performed to determine whether IP-10 or MIG was required for bacterial clearance in animals with Klebsiella pneumonia. In these experiments, animals were administered either rabbit polyclonal anti-murine IP-10 or control IgG (5 mg) or monoclonal anti-murine MIG antibody (clone 2A6.9.9) or control IgG (100 μg) 2 h prior to *K. pneumoniae* inoculation (5 × 10^2^ CFU), and then one-half of the original antibody dose was administered 48 h later.
Lungs and blood were harvested on days 1, 2, and 3 after bacterial challenge for the assessment of *K. pneumoniae* CFU. As shown in Fig. 4A, the administration of anti-IP-10 antibody resulted in approximately 10- and 100-fold increases in the number of *K. pneumoniae* CFU isolated from lung homogenates recovered from animals 2 and 3 days after *Klebsiella* administration, respectively, relative to animals receiving control IgG (P < 0.05). Similarly, i.p. administration of anti-IP-10 antibody resulted in an increase in bacterial burden in blood, with approximately 24- and 31-fold increases in the number of *K. pneumoniae* CFU observed at 2 and 3 days after *Klebsiella* administration, respectively, relative to animals receiving control IgG (Fig. 5B). To confirm these results, we performed additional studies using a hamster anti-murine IP-10 antibody that has been shown to effectively neutralize IP-10 in a systemic murine *Toxoplasma gondii* model (17). Like results obtained using the polyclonal antibody, we found that the i.p. administration of hamster anti-IP-10 antibody resulted in a similar increase in lung and blood *K. pneumoniae* CFU relative to animals receiving control antibody (data not shown).

In contrast to the impaired clearance of bacteria observed with antibody-mediated IP-10 neutralization, we observed no difference in lung or blood *K. pneumoniae* CFU in animals pretreated with monoclonal anti-murine MIG antibody (100 μg) at 2 and 3 days after bacterial challenge relative to animals receiving control IgG (Fig. 4B). The failure of the anti-murine MIG antibody to alter clearance was not attributable to an inability to effectively neutralize MIG, as the administration of this antibody substantially reduced MIG levels in lungs of *Klebsiella*-infected animals and has been shown to be effective in other animal model systems (41).

**FIG. 3.** Expression of IP-10 and MIG mRNA and protein in lungs of wild-type (wt) and IFN-γ⁻/⁻ mice challenged with *K. pneumoniae*. For mRNA analysis, lungs were harvested 48 h after bacterial administration and chemokine mRNA levels were determined by quantitative real-time PCR (A). For protein analysis, lungs were harvested 48 and 72 h after bacterial administration and chemokine protein levels were determined by ELISA. For real-time PCR four lungs per group per time point were combined and averaged and represent fold increase over uninfected control. For protein analysis, n was six lungs per group per time point and data presented are a composite of two separate experiments. *, P was < 0.05 compared to that for the uninfected control. **, P was < 0.01 compared to that for the uninfected control or infected IFN-γ knockout (ko) mice. kp, *Klebsiella*-infected mice.
Effect of anti-murine IP-10 antibody administration on survival in murine Klebsiella pneumonia. Having determined that the neutralization of IP-10, but not MIG, impaired the clearance of bacteria from the lung, we next assessed the effect of anti-IP-10 antibody administration on survival in mice infected with K. pneumoniae. In these experiments, animals were administered anti-IP-10 antibody or control IgG (5 mg) i.p. and then 2.5 mg antibody every 48 h throughout the duration of the study. Two hours following the initial antibody administration, animals received K. pneumoniae (5 \times 10^3 CFU) i.t., and then effects on survival were determined. As shown in Fig. 5, the neutralization of IP-10 significantly decreased survival, as <20% of anti-IP-10-treated animals survived long-term (more than 10 days postinoculation), whereas 60% of infected animals receiving control IgG survived ($P < 0.05$).

Effect of anti-murine IP-10 antibody administration on lung leukocyte influx in murine Klebsiella pneumonia. To determine if the detrimental effects of IP-10 neutralization on bacterial clearance and survival were attributable to alterations in lung leukocyte influx, numbers of lung leukocytes were quantitated in control IgG- and anti-IP-10-treated animals. Animals were administered control or anti-IP-10 antibodies 2 h prior to and 48 h after K. pneumoniae inoculation (5 \times 10^3 CFU), and then lungs were harvested at 24 and 72 h postinfection and total leukocyte populations were quantitated by lung digestion. The i.t. administration of K. pneumoniae resulted in a maximal 2.5-fold increase in total numbers of lung leukocytes at 72 h (data not shown), with the greatest increase observed in the number of neutrophils and a smaller increase observed in mononuclear cells (mononuclear phagocytes plus lymphocytes). Interestingly, the administration of anti-IP-10 antibody resulted in a significant increase in the number of neutrophils in the lung, most notable at 72 h after infectious challenge ($P$ was $< 0.05$ compared to that for the control IgG group) (Fig. 6). No change in total number of mononuclear cells was noted at either time point (data not shown). Also, no change in either

FIG. 4. Effect of IP-10 or MIG neutralization on bacterial clearance in Klebsiella-infected mice. Animals were administered either purified rabbit control IgG, purified rabbit anti-murine IP-10 antibody (5 mg) i.p. or monoclonal hamster anti-murine IP-10 antibody (100 \mu g) 2 h before and 2.5 mg every 48 h after the administration of K. pneumoniae (5 \times 10^3 CFU). Panel A represents effects of anti-IP-10 on lung (left) and blood (right) K. pneumoniae CFU at 1, 2, and 3 days after infectious challenge expressed on a log_{10} scale. Panel B represents the effect of MIG neutralization on lung (left) and blood (right) K. pneumoniae CFU at 2 and 3 days after infectious challenge expressed on a log_{10} scale. *, $P$ was $< 0.05$ compared to that for mice receiving control IgG. Experimental $n$ was five to eight animals per time point, and data presented are a composite of two separate experiments. kp, Klebsiella-infected mice.
neutrophil or mononuclear cell influx was observed in animals pretreated with anti-MIG antibody prior to i.t. bacterial challenge (data not shown).

To determine whether anti-IP-10 antibody administration altered the influx and/or activation of selected T-cell and NK-cell populations, C57BL/6 mice were administered control IgG or anti-IP-10 antibody i.p., followed 2 h later by the i.t. administration of K. pneumoniae (5 × 10^5 CFU). *, P was <0.05 compared to that of mice receiving control IgG. Experimental n was 20 to 22 animals per group, and data presented are a composite of two separate experiments. kp, Klebsiella-infected mice.

![FIG. 5. Effect of IP-10 neutralization on survival in Klebsiella-infected mice. Animals were administered either purified rabbit control IgG or purified rabbit anti-murine IP-10 antibody (5 mg) i.p. 2 h before and a one-half dose every 48 h after the administration of K. pneumoniae (5 × 10^3 CFU).](*, P was <0.05 compared to that of mice receiving control IgG. Experimental n was 20 to 22 animals per group, and data presented are a composite of two separate experiments. Kp, Klebsiella-infected mice.)

**FIG. 6. Effect of IP-10 neutralization on lung neutrophil influx after i.t. K. pneumoniae administration.** Animals were administered either purified rabbit control IgG or purified rabbit anti-murine IP-10 antibody (5 mg) i.p. 2 h before and a one-half dose every 48 h after the administration of K. pneumoniae (5 × 10^5 CFU). *, P was <0.05 compared to that for mice receiving control IgG. Experimental n was five to seven animals per group, and data presented are a composite of two separate experiments. kp, Klebsiella-infected mice.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Treatment type</th>
<th>CD4^+</th>
<th>CD8^+</th>
<th>αβ TCR^+</th>
<th>γδ TCR^+</th>
<th>DX5^+</th>
<th>αβ/γδ TCR^+</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4^+</td>
<td>Uninfected</td>
<td>21.66</td>
<td>5.91</td>
<td>10.15</td>
<td>0.57</td>
<td>5.41</td>
<td>0.09</td>
</tr>
<tr>
<td>CD8^+</td>
<td>Kp/IgG</td>
<td>37.34</td>
<td>4.62</td>
<td>5.21</td>
<td>0.55</td>
<td>5.41</td>
<td>0.09</td>
</tr>
<tr>
<td>αβ TCR^+</td>
<td>Kp/αIP-10</td>
<td>34.44</td>
<td>6.56</td>
<td>0.93</td>
<td>0.16</td>
<td>9.29</td>
<td>0.02</td>
</tr>
<tr>
<td>γδ TCR^+</td>
<td></td>
<td>8.93</td>
<td>0.16</td>
<td>1.76</td>
<td>0.41</td>
<td>10.59</td>
<td>0.09</td>
</tr>
<tr>
<td>DX5^+</td>
<td></td>
<td>9.29</td>
<td>0.24</td>
<td>14.34</td>
<td>0.52</td>
<td>11.84</td>
<td>0.11</td>
</tr>
<tr>
<td>αβ/γδ TCR^+</td>
<td></td>
<td>1.76</td>
<td>0.30</td>
<td>5.44</td>
<td>0.84</td>
<td>2.51</td>
<td>0.24</td>
</tr>
</tbody>
</table>

* Cells are expressed as cell number × 10^6. n was three to six per group, and data presented are a composite of two separate experiments. Kp, Klebsiella-infected mice.

**TABLE 1. Effect of IP-10 neutralization of accumulation of mononuclear cells in lung 72 h after i.t. K. pneumoniae administration.**

![Downloaded from http://iai.asm.org/ on August 27, 2017 by guest](http://iai.asm.org/)
there is a striking accumulation of bacteria within phagolysosomes, which could occur as a result of a greater burden of organisms within the airspace or, more likely, as a consequence of impaired ability to kill ingested organisms.

**Effect of anti-IP-10 antibody administration on the expression of IFN-γ mRNA in murine Klebsiella pneumonia.** Because our data suggest that neutrophils and macrophages isolated from anti-IP-10-treated animals displayed impaired killing of ingested organisms and IP-10 has been shown to directly stimulate IFN-γ production from T cells and mediate the accumulation of IFN-γ-producing cells, we next assessed the effect of IP-10 neutralization on the expression of IFN-γ mRNA in the lungs of Klebsiella-infected mice. In these studies, mice were administered either control IgG or rabbit anti-mouse IP-10 antibody i.p. and challenged with Klebsiella pneumoniae, and then IFN-γ mRNA levels were determined in lung homogenates at various time points by real-time quantitative PCR. As shown in Fig. 9, there was a significant induction of IFN-γ message (27-fold increase) in lung homogenate of Klebsiella-infected mice, peaking at 48 h after bacterial administration and decreasing by 72 h. In comparison, peak IFN-γ mRNA expression was significantly blunted in the lungs of infected animals receiving anti-IP-10 antibody ($P < 0.05$ relative to that for infected control animals).

**Effect of adenovirus-mediated transgenic expression of IP-10 on bacterial clearance in murine Klebsiella pneumonia.** Having shown that antibody-mediated neutralization of IP-10 resulted in impaired lung antibacterial host defense, we next evaluated the effect of intrapulmonary transient transgenic expression of IP-10 on clearance of Klebsiella pneumoniae from the lung. To accomplish this, we inserted the murine IP-10 or a control gene into a human E1, partial E3-deleted recombinant adenovirus. The i.t. administration of 10^9 PFU of recombinant IP-10-containing adenovirus (Ad IP-10) resulted in a fivefold increase in IP-10 in lung homogenates, maximal at 24 h postadministration (40). Importantly, the administration of Ad...
IP-10 (10^9 PFU) i.t. concomitant with *K. pneumoniae* (5 × 10^3 CFU) resulted in a nearly 100-fold reduction in bacterial CFU in lung harvest 3 days later, compared to that of infected animals receiving control adenovirus i.t. (Fig. 10, *P* < 0.05). Additionally, adenovirus-mediated expression of IP-10 resulted in 30-fold and more than 100-fold reductions in blood CFU at day 2 (*P*, 0.05) and day 3 (*P*, 0.10) after bacterial administration, respectively.

**DISCUSSION**

Our studies indicate that the intrapulmonary challenge with *K. pneumoniae* results in marked induction of IP-10 and MIG expression and that IP-10, but not the MIG, contributes substantially to host innate responses against this virulent bacterial pathogen. IP-10 and/or MIG has previously been shown to contribute to host defense against several intracellular microbial pathogens and viruses (2, 17, 18, 37). In the current study, we found that IP-10 is an important component of lung innate immunity against extracellular gram-negative bacteria that are highly relevant respiratory pathogens in humans.

We found that i.t. bacterial administration resulted in the early expression of IP-10 mRNA in lung, with a somewhat delayed expression (approximately 24 h later) of the MIG message. Furthermore, we observed that the expression of MIG in *Klebsiella pneumoniae* required the endogenous production of IFN-γ, whereas IP-10 expression was detected in IFN-γ-deficient mice challenged with *K. pneumoniae*, albeit considerably diminished compared to that found in wild-type animals. Our findings are consistent with that of Neumann and associates, who observed that the production of both MIG and IP-10 was largely IFN-γ dependent in a staphylococcal enterotoxin B model of lung inflammation (26). In addition, intrapulmonary bacterial administration resulted in considerable systemic expression of both IP-10 and MIG in a time frame similar to that observed in lung. The early induction of IP-10 may occur as a direct result of bacterial exposure or perhaps in response to host-derived genes, including TNF-α and heat shock protein, expressed early in the innate response (reference 11 and unpublished observations). In contrast, MIG expression is likely delayed relative to IP-10 due to the absolute requirement for IFN-γ, which is not maximally expressed in *Klebsiella pneumoniae* until at least 48 h after bacterial challenge. Early expression of IFN-γ in the lung during pneumonia is derived from several cellular sources, including NK cells, γδ-T cells, and perhaps pulmonary macrophages (8, 9, 23).

Mechanisms by which IP-10 promotes effective innate responses in the lung have been incompletely defined. However, our findings indicate that neutralization of IP-10 results in significant reductions in the number or activational status of IFN-γ-producing cells in the lung, including NK cells, NK-T cells, CD4^+^ T cells, and γδ-T cells. Moreover, antibody-mediated neutralization of IP-10 resulted in a significant decrease in the intrapulmonary expression of IFN-γ mRNA in pneumonia. This reduction in IFN-γ could result from impaired recruitment of IFN-γ-producing cells or, alternatively, may be attributable to loss of direct stimulatory effects of IP-10 on IFN-γ production from effector T cells (12). Our in vivo findings are consistent with known in vitro chemotactic effects of IP-10 on specific NK, T, and NK-T cell populations (11, 12, 33). We and
others have also shown that the transient transgenic expression of IP-10 within the lung results in the accumulation of NK cells, NK-T cells, and CD4⁺ T cells, as well as an increase in the number of activated T cells and NK cells, as manifested by CD69 expression and intracellular IFN-γ expression (27, 40). Given that IFN-γ is a key activator of both neutrophil and alveolar macrophage antimicrobial function (19, 29, 31), reduced IFN-γ responses readily explain the impaired killing of internalized bacteria, as observed in neutrophils and alveolar macrophages isolated ex vivo from anti-IP-10-treated mice.

Interestingly, we found an increased number of neutrophils within the lungs of infected animals receiving anti-IP-10 antibody. Neither IP-10 nor other ELR⁺ CXC chemokines exert direct chemotactic effects on neutrophils in vitro. However, the transient transgenic expression of mouse or human IP-10 in rodents can induce lung neutrophilia in vivo, and this effect occurs in a T-cell-dependent fashion (27, 40). The most plausible explanation for enhanced neutrophil influx is that this response is being driven by the increased bacterial burden in lungs of anti-IP-10-treated mice. These findings would also argue against a direct stimulatory effect of IP-10 on neutrophil migration.

We observed an important role of IP-10, but not MIG, in lung antibacterial host defense. The specificity of chemokine responses is somewhat surprising, given that in vitro chemotactic and activating effects are similar and these chemokines signal through a common receptor (11, 12, 21). Direct comparisons of IP-10 and MIG in type 1 immune responses, particularly in infection, have not been reported. Others have noted disparate regulation of IP-10 and MIG in other inflammatory conditions, including infection (37). These observations support the notion that specific ELR⁺ CXC chemokines are functionally distinct, and there is not complete redundancy in biological effects in vivo.

A possible mechanism that could account for the lack of anti-MIG antibody effects is a compensatory increase in IP-10 in Klebsiella-infected animals in which MIG has been neutralized. However, we failed to observe changes in IP-10 in animals receiving anti-MIG antibodies relative to infected mice receiving control IgG (data not shown).

Our findings differ somewhat from that reported by Wiedny and associates (38). Specifically, these investigators found that mice which were deficient in CXCR3 had impaired lymphocyte and NK-cell influx in response to intrapulmonary challenge with the gram-negative cocobacillus B. bronchiseptica but displayed only modest defects in bacterial clearance compared to that of wild-type controls. The disparity in our findings may be partially attributable to differences in the virulence of the bacterial pathogen used, as K. pneumoniae is an encapsulated, highly virulent pathogen that requires maximal neutrophil and alveolar macrophage effector responses, whereas B. bronchiseptica is considerably less virulent and the nature of protective responses against this pathogen has been only partially defined (14). Also, the aforementioned study utilized mice which had a life-long deficiency in CXCR3 and, as a result, may have developed alternative pathways to compensate for the absence of this receptor. Moreover, by blocking the effects of the entire ELR⁺ CXC chemokine family, disparate and perhaps opposing effects of various family members might considerably confound the phenotype expressed.

The intrapulmonary transient transgenic expression of IP-10 resulted in a significant improvement in bacterial clearance in mice with Klebsiella pneumonia. The mechanism of this improved clearance has not yet been defined. However, we have previously shown that adenovirus-mediated IP-10 expression resulted in augmented accumulation of IFN-γ-producing cells, including NK, NK-T, and CD4⁺ T cells (40). These results are consistent with the protective effects on pulmonary innate immunity when other type 1 cytokines, including interleukin-12 and IFN-γ, are compartmentally expressed in lung in murine models of pneumonia due to both extracellular and intracellular bacterial pathogens (8, 13, 19). These findings support a potential role for IP-10 as a candidate for immunoadjuvant therapy, especially in conditions of impaired type 1 immune responses.

ACKNOWLEDGMENTS

This work was supported by NIH grants PO50 HL60289 and HL57243 (T.J.S.).

REFERENCES


Editor: J. N. Weiser